viewImmuPharma PLC

ImmuPharma expects second phase III lupus trial to get underway as soon as possible this year

The UK company and its American partner concluded their first joint steering committee recently

ImmuPharma PLC -

ImmuPharma PLC (LON:IMM) has hailed the “positive and proactive” progress made by it and partner Avion Pharmaceuticals that will see a second phase III trial of the latter’s drug for lupus get underway “as soon as possible” this year.

The pair will meet America’s Food & Drug Administration sometime this quarter to seek guidance for an optimised study of Lupuzor.

In the update, ImmuPharma said there had been a number of discussions with a number of potential commercial partners outside the US – hinting at further commercial upside for the drug.

The Avion deal, announced in November, will see ImmuPharma receive up to US$70mln of milestone payments, with US$5mln due on regulatory approval of the product and a further US$65mln dependent on sales targets.

The UK group will also get royalties of up to 17% on sales, while there are financial incentives to expand Lupuzor’s use into other autoimmune diseases.

 “We are in a new chapter within ImmuPharma's history, with the investment thesis for the company and specifically Lupuzor being repositioned and we look forward to providing further updates on progress with shareholders over the next period," said chief executive Dimitri Dimitriou.

Quick facts: ImmuPharma PLC

Price: 9.2 GBX

Market: AIM
Market Cap: £23.02 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...


Immupharma: The Life Sciences Division's Dr Malik says shares are 'oversold'...

The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on ImmuPharma PLC (LON:IMM). Malik examines the company's flagship drug Lupuzor - a treatment for the autoimmune disease Lupus. ImmuPharma recently updated the market on progress within its lupus drug, Lupuzor,...

2 weeks, 2 days ago

2 min read